Chimeric VLP Based Vaccines
In recent years, the use of chimeric virus-like particles as vaccines and gene vectors has gained increasing attention in both basic and applied research. Chimeric VLPs pave the way for the development of vaccine candidates with a broader, more powerful and comprehensive protection against diseases. Creative Biolabs has long-term devoted to the development of vaccine technology. We offer chimeric VLP based vaccines design services according to customers' need.
An important and forthcoming application of VLPs is their use for the generation of immune responses against foreign protein epitopes by genetically fusing or chemically conjugating them to VLPs of different origins, resulting in a so-called chimeric VLP. The chimeric VLPs consist of viral proteins while envelope proteins are from the second virus. The envelope protein can serve as a signal for a particular tissue receptor so that VLP can be targeted to a particular tissue with the capsid protein conjugated with the targeting component.
Several chimeric vaccines have entered clinical trials, including the anti-influenza A M2–HBcAg VLP vaccine, the anti-HIV p17/p24: Ty VLP, two antimalaria vaccines, the nicotine-Qb VLP and the anti-Ang II Qb VLP. Other chimeric VLP vaccine candidates undergoing preclinical evaluation are presented in Table 1.
Table 1. Examples of chimeric VLPs in preclinical development. [1]
| VLP platform | Chimeric antigen and plasmids | Expression system |
|---|---|---|
| BPV | CTL epitopes of HPV and HIV, L2 HPV epitopes, Aβ1–9 peptide | B/IC |
| HBV (core) | GFP, bacterial and protozoan epitopes, HPV-16 E7 oncoprotein epitopes, B- and T-cell epitopes of HCV, Plasmodium falciparum circumsporozoite protein epitopes (malaria vaccine candidate), M2 of influenza A‡ and FMDV VP1 | Bacteria (E. coli) |
| HBV (surface) | Plant signal peptides, dengue virus envelope, HIV gp41 2F5 epitope, HCV HVR1, HPV-16 E7 oncoprotein epitopes, GFP, VSPαS | Mammalian cells, transgenic plants (tobacco cells), bacteria (E. coli) and yeast (Pichia pastoris) |
| HEV | HEV B-cell epitope | B/IC |
| HIV, SHIV gag | Various HIV envelope epitopes, RT or TN proteins, gp120 and pol, and influenza A HA | B/IC and mammalian cells |
Expressed VLPs are derived from hepatitis B virus core or surface protein, HIV gag protein, papilloma virus, rhinovirus and various plant viruses. The classical expression systems of these particles in animal cell cultures are complemented by expression in yeast and transgenic plants. The advantages provided by certain chimeric particles, such as induction of cytolytic T lymphocyte immune responses after administration of recombinant HBsAg, make VLPs promising candidates for new vaccines. DNA vaccination is also considered as a further novel model of protection against infectious agents.
Creative Biolabs is professional in a wide range of vaccine technologies including chimeric VLP based vaccines. We are confident in providing the best services for our clients all over the world.
Reference
- Roldão, A. (2010). “Virus-like particles in vaccine development.” Expert Rev Vaccines. 9(10), 1149-1176.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
